BHIVA Debate - Interferon-sparing regimens for hepatitis C
This house believes that we should treat hepatitis C with pegylated interferon and direct-acting antivirals rather than wait for interferon-free options.
For the motion:
Dr Mark Nelson, Chelsea and Westminster Hospital, London
Against the motion:
Dr Sanjay Bhagani, Royal Free Hospital, London
Click here to go back to all presentations.